Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ocular Therapeutix stock | $6.91

Learn how to easily invest in Ocular Therapeutix stock.

Ocular Therapeutix Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 181 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ocular Therapeutix

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OCUL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ocular Therapeutix stock price (NASDAQ: OCUL)

Use our graph to track the performance of OCUL stocks over time.

Ocular Therapeutix shares at a glance

Information last updated 2021-10-17.
Latest market close$6.91
52-week range$9.11 - $24.30
50-day moving average $10.62
200-day moving average $13.02
Wall St. target price$23.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.95

Buy Ocular Therapeutix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ocular Therapeutix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocular Therapeutix price performance over time

Historical closes compared with the close of $6.91 from 2021-10-22

1 week (2021-10-15) -38.25%
1 month (2021-09-24) -34.13%
3 months (2021-07-23) -44.05%
6 months (2021-04-23) -55.29%
1 year (2020-10-23) -32.12%
2 years (2019-10-24) 115.26%
3 years (2018-10-24) 30.62%
5 years (2016-10-24) 2.07%

Ocular Therapeutix financials

Revenue TTM $32.3 million
Gross profit TTM $-13,374,000
Return on assets TTM -25.45%
Return on equity TTM -240.48%
Profit margin 0%
Book value $1.05
Market capitalisation $857 million

TTM: trailing 12 months

Shorting Ocular Therapeutix shares

There are currently 5.2 million Ocular Therapeutix shares held short by investors – that's known as Ocular Therapeutix's "short interest". This figure is 10.6% down from 5.8 million last month.

There are a few different ways that this level of interest in shorting Ocular Therapeutix shares can be evaluated.

Ocular Therapeutix's "short interest ratio" (SIR)

Ocular Therapeutix's "short interest ratio" (SIR) is the quantity of Ocular Therapeutix shares currently shorted divided by the average quantity of Ocular Therapeutix shares traded daily (recently around 706550.33921303). Ocular Therapeutix's SIR currently stands at 7.37. In other words for every 100,000 Ocular Therapeutix shares traded daily on the market, roughly 7370 shares are currently held short.

However Ocular Therapeutix's short interest can also be evaluated against the total number of Ocular Therapeutix shares, or, against the total number of tradable Ocular Therapeutix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocular Therapeutix's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Ocular Therapeutix shares in existence, roughly 70 shares are currently held short) or 0.0776% of the tradable shares (for every 100,000 tradable Ocular Therapeutix shares, roughly 78 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ocular Therapeutix.

Find out more about how you can short Ocular Therapeutix stock.

Ocular Therapeutix share dividends

We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.

Ocular Therapeutix share price volatility

Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $9.11 up to $24.3. A popular way to gauge a stock's volatility is its "beta".

OCUL.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 2.1042. This would suggest that Ocular Therapeutix's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Ocular Therapeutix overview

Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration.

Frequently asked questions

What percentage of Ocular Therapeutix is owned by insiders or institutions?
Currently 0.393% of Ocular Therapeutix shares are held by insiders and 64.581% by institutions.
How many people work for Ocular Therapeutix?
Latest data suggests 181 work at Ocular Therapeutix.
When does the fiscal year end for Ocular Therapeutix?
Ocular Therapeutix's fiscal year ends in December.
Where is Ocular Therapeutix based?
Ocular Therapeutix's address is: 24 Crosby Drive, Bedford, MA, United States, 01730
What is Ocular Therapeutix's ISIN number?
Ocular Therapeutix's international securities identification number is: US67576A1007
What is Ocular Therapeutix's CUSIP number?
Ocular Therapeutix's Committee on Uniform Securities Identification Procedures number is: 67576A100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site